Drugs / Sotrovimab
Sotrovimab
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Xevudy | — | 2026-02-18 | europa.eu ↗ |
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05280717 | Mar 2022 → Apr 2023 | COVID-19 | Vir Biotechnology, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05135650 | Jan → Oct 2022 | COVID-19, cancer, hematopoietic and lymphoid cell neoplasm | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT04988152 | Jul → Sep 2021 | COVID-19 | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05210101 | Feb 2022 → Feb 2023 | COVID-19 | Sophia Koo, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT05124210 | Dec 2021 → Jun 2023 | COVID-19 | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT05041907 | Sep 2021 → Jan 2027 expected | COVID-19 | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT04634409 | Oct 2020 → Jul 2021 | COVID-19 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04870333 | Feb 2021 → Apr 2025 | COVID-19 | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2/3 | NCT04545060 | Aug 2020 → Apr 2021 | COVID-19 | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05205759 | Dec 2021 → Feb 2022 | COVID-19 | Azienda Ospedaliera Universitaria Integrata Verona | Terminated | No outcome recorded |
| Phase 3 | NCT04913675 | Jun 2021 → Jul 2022 | COVID-19 | Vir Biotechnology, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05780281 | Dec 2020 → Jun 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04501978 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04790786 | Mar 2021 → Jun 2022 | COVID-19 | Erin McCreary | Terminated | No outcome recorded |
| Phase 4 | NCT04748588 | Feb 2021 → Jan 2022 | COVID-19, nosocomial infection | University of Calgary | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05235347 | — | COVID-19 | Vir Biotechnology, Inc. | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04746183 Comparator | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04779879 Comparator | Feb → Aug 2021 | COVID-19 | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05271929 Background | Apr 2022 → Jan 2024 | COVID-19 | German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen | Terminated | No outcome recorded |
| Phase 3 | NCT05321394 Comparator | Mar 2022 → Oct 2023 | COVID-19 | Azienda Ospedaliera Universitaria Integrata Verona | Completed | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05305651 Background | Jul 2022 → Jul 2023 | COVID-19 | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sotrovimab | “Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.” NCT04748588 ↗ |
| Known as | GSK4182136 | “Sotrovimab, VIR-7831, GSK4182136 Sterile solution for intravenous infusion, 62.5 mg/mL, intravenous infusion” NCT04870333 ↗ |
| Known as | SOT | “500 mg of intravenous sotrovimab (SOT)” PMID 39343244 ↗ Sep 2024 |
| Known as | VIR-7831 | “This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2...” NCT04779879 ↗6“Sotrovimab, VIR-7831, GSK4182136 Sterile solution for intravenous infusion, 62.5 mg/mL, intravenous infusion” NCT04870333 ↗ “VIR-7831 (sotrovimab) given by intravenous infusion (single dose)” NCT04545060 ↗ |
| Known as | Xevudy | “Sotrovimab (Xevudy)” NCT05271929 ↗ |
| Action | Inhibit | “neutralising monoclonal antibody” PMID 40886716 ↗ Aug 2025 |
| Modality | Monoclonal antibody | “neutralising monoclonal antibody” PMID 40886716 ↗ Aug 2025 |
| Route | Intravenous | “by intravenous infusion” NCT04381936 ↗ |